BioPharma Today

China: The New Land of Opportunity for Biopharma Companies?

The pharmaceutical and life sciences landscape is changing fast in China. There are close to 1,000 bio-related companies in China, and half were established in the last five years or so. Citi expects China’s pharmaceutical market to grow from its current level of $40 billion to $100 billion by 2015 and to $200 billion by 2020, which will make it the second largest in the world, passing Japan along the way.

Opposition Party Lawmaker Criticizes Korean Government's Retreat From Funding Vaccinations

Article reprinted from "PharmAsia News"- October 12, 2010

SEOUL - A minor opposition party lawmaker accused the Korean government of backing down from its earlier stance to help fund compulsory vaccinations for diseases such as hepatitis B.

Pfizer Vaccines President Mark Swindell On Prevenar 13 in Developing Countries And Emerging Markets: An Interview With PharmAsia News

Article preview from "PharmAsia News"- September 13, 2010

Pfizer and GlaxoSmithKline attracted attention earlier this year while finalizing an agreement with the public-private GAVI Alliance to bring the newest pneumococcal vaccines - Prevenar 13 and Synflorix, respectively - to developing countries.

Latest News from "The Pink Sheet" DAILY - Dendreon Set To Ship Provenge Soon

Dendreon Set To Ship Provenge Within A Week

Demand expected to exceed supply as company builds manufacturing capacity.   read more

Coming in Wednesday's "The Pink Sheet" DAILY - Legal Updates for Merck, AstraZeneca

Hospira has voluntarily suspended shipments of two drugs – Propofol, an anesthesia, and Liposyn, a fat emulsion for low birth weight babies – to address manufacturing concerns raised by FDA in a recent warning letter.

Latest News from "The Pink Sheet" DAILY - Novartis' Sandoz Unit Makes Respiratory Push

Pharmerging Markets Expected To Keep Sales Growth "Strong" Through 2014, IMS Says

IMS forecasts a 5 percent to 8 percent growth of global pharmaceutical sales annually through 2014. read_more_>

Coming In Tuesday's "The Pink Sheet" DAILY - Merck Pipeline News and FDA Advisory Committee Mtgs. On Tap

Merck unveils integrated late-stage pipeline, including 40 Phase II and Phase III medicines of which eight are in the areas of cardiovascular or infectious disease.

Latest News from "The Pink Sheet" DAILY - Salix's Xifaxan Advisory Panel Review

Salix's Xifaxan Draws Ambivalent Recommendation From Advisory Panel

Salix's Xifaxan for hepatic encephalopathy passed advisory committee review, but members expressed unease about lingering safety concerns and called for additional studies. read_more_>

Latest News from "The Pink Sheet" DAILY -- Merck Unveils Gardasil Data

Merck Looks To Mid-June FDA Decision On Expanded Use Of Gardasil To Older Women

Company unveils data at European conference supporting use in women ages 27 through 45; data was sent to FDA late last year.   read more

Latest News from "The Pink Sheet" DAILY

Notes From J.P. Morgan: Daschle Disses DTC

A collection of dispatches from the J.P. Morgan health care conference in San Francisco.   read more